Core 1: Biospecimen and Pathology Core

核心1生物显微镜与病理学：摘要/摘要 生物检疫和病理核心将协调与收集、加工、储存和 为所有孢子项目分发带注释的人类和小鼠生物标本，包括职业 增强计划(CEP)和发展研究计划(DRP)。核心将由两个人共同领导 全国知名的胃肠/胰腺病理学家Maru Dipen Maru博士和王华民博士。对于人类来说 生物质谱学，核心将与MDACC机构组织库(ITB)对接。生物菌种资源 来自下胃肠道组织库包括新鲜收集/快速冷冻和福尔马林固定的石蜡 2500多例肝转移癌(包括 新鲜采集的334例患者的冰冻腺瘤，福尔马林固定的石蜡包埋 870例或以上散发性腺瘤或家族性腺瘤性息肉病患者的标本。现有 可在胰腺银行和相关IRB批准的方案中使用的生物素资源包括 收集/抓取Whiple切除胰腺管的冰冻肿瘤和正常组织标本 来自232例患者的腺癌，福尔马林固定的石蜡包埋标本和另外672例 患者，包括来自胰腺导管腺癌和导管内胰腺癌的组织芯片 粘液性肿瘤。该核心将通过协调未来的血液采集来支持项目1， 冷冻保存和与ITB一起运输。具体地说，核心教员将前瞻性地收集、处理和 肝脏结直肠癌转移瘤新鲜标本及正常标本镜像后的分布 组织学质控科室。核心将提供福尔马林固定的石蜡包埋样本正常， 腺瘤和癌。此外，该中心还将提供生物检疫鉴定服务， 包括但不限于，使用STAT3处理的人和小鼠组织的组织病理学特征 抑制物，免疫组织化学染色和解释，包括验证p-STAT3染色 CLIA认证设施中的自动化图像分析。核心将提供新切除的PDAC样本，用于 项目3的患者来源的异种移植和体外活体组织敏感性分析(LTSA)。此外，核心将 为两者提供组织病理学特征、免疫组织化学服务和解释指南 正在进行的联合临床试验的临床前样本，以及从这两个组织获得的一系列组织活检 正在进行的临床试验项目3。该中心还将协调适当样本的分配 调查人员通过孢子CEP和DRP赠款提供资金。核心人员将与ITB一起， 输入与生物菌素收集、加工、鉴定、分配的所有流程相关的详细信息 并将分析结果提取到名为“组织站”的机构生物信息学平台中。这个 核心活动将导致卫生纸站这些功能的增强，并设计一个新的界面 组织站中的胃肠道孢子。

CORE 1 BIOSPECIMEN AND PATHOLOGY: Summary/Abstract The Biospecimen and Pathology Core will coordinate efforts related to collection, processing, storage and distribution of annotated human and murine biospecimens for all of the SPORE projects, including the Career Enhancement Program (CEP) and Developmental Research Program (DRP). The Core will be co-led by two nationally reputed gastrointestinal/pancreatic pathologists, Drs. Dipen Maru and Huamin Wang. For human biospecimens, the core will interface with the MDACC Institutional Tissue Bank (ITB). Biospecimen resources from the lower gastrointestinal tissue bank include freshly collected/snap frozen and formalin fixed paraffin embedded tumor and normal specimens from more than 2500 resected hepatic colorectal metastases (including TMAs), freshly collected and snap frozen adenoma from 334 patients and formalin fixed paraffin embedded specimens from 870 or more patients with sporadic adenoma or familial adenomatous polyposis. Existing biospecimen resources available in the pancreatic bank and related IRB approved protocols include freshly collected/snap frozen tumor and normal tissue sample from Whipple resection for pancreatic ductal adenocarcinoma from 232 patients, with formalin fixed paraffin embedded specimens and additional 672 patients, including tissue microarrays from pancreatic ductal adenocarcinoma and intraductal pancreatic mucinous neoplasms. The Core will support Project 1 by coordinating prospective blood collection, cryopreservation and transport with the ITB. Specifically, Core faculty will prospectively collect, process and distribute fresh tumor and normal samples from hepatic colorectal metastases after obtaining mirror image section for histology quality control. The Core will provide formalin fixed paraffin embedded samples of normal, adenoma and carcinoma to Project 2. In addition the Core will provide biospecimen qualification services, including but not limited to, histopathologic characterization of human and murine tissues treated with STAT3 inhibitor, and immunohistochemistry staining and interpretation, including validation of p-STAT3 staining by automated image analysis in a CLIA-certified facility. The Core will provide freshly resected PDAC samples for patient derived xenografts and ex vivo live tissue sensitivity assay (LTSA) for Project 3. In addition, the Core will provide histopathology characterization, immunohistochemistry services and interpretation guidelines for both preclinical samples from the ongoing co-clinical trials, as well as serial tissue biopsies obtained from the two clinical trials being conducted Project 3. The Core will also coordinate distribution of appropriate samples to investigators funded through the SPORE CEP and DRP grants. The Core personnel, along with the ITB, will enter detailed information related to all processes of biospecimen collection, processing, qualification, distribution and analytes extraction into the Institutional Biospecimen Informatics platform known as “Tissue Station”. The Core activities will lead to enhancement of these functionalities of Tissue Station and design a new interface specific for GI SPORE in the Tissue Station.